• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Eemerging evidence and future perspectives

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Kato, T.
    Casarini, I.
    Cobo, M.
    Faivre-Finn, Corinne
    Hegi-Johnson, F.
    Lu, S.
    Özgüroğlu, M.
    Ramalingam, S. S.
    Affiliation
    University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom.
    Issue Date
    2024
    
    Metadata
    Show full item record
    Abstract
    Epidermal growth factor receptor (EGFR) mutations are detected in up to one third of patients with unresectable stage III non-small cell lung cancer (NSCLC). The current standard of care for unresectable stage III NSCLC is consolidation durvalumab for patients who have not progressed following concurrent chemoradiotherapy (the 'PACIFIC regimen'). However, the benefit of immunotherapy, specifically in patients with EGFR mutation-positive (EGFRm) tumors, is not well characterized, and this treatment approach is not recommended in these patients, based on a recent ESMO consensus statement. EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated significant improvements in patient outcomes in EGFRm metastatic NSCLC. The benefits of these agents have also translated to patients with EGFRm early-stage resectable disease as adjuvant therapy. The role of EGFR-TKIs has yet to be prospectively characterized in the unresectable setting. Preliminary efficacy signals for EGFR-TKIs in unresectable EGFRm stage III NSCLC have been reported from a limited number of subgroup and retrospective studies. Several clinical trials are ongoing assessing the safety and efficacy of EGFR-TKIs in this patient population. Here, we review the current management of unresectable EGFRm stage III NSCLC. We outline the rationale for investigating EGFR-TKI strategies in this setting and discuss ongoing studies. Finally, we discuss the evidence gaps and future challenges for treating patients with unresectable EGFRm stage III NSCLC.
    Citation
    Kato T, Casarini I, Cobo M, Faivre-Finn C, Hegi-Johnson F, Lu S, et al. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives. Lung cancer (Amsterdam, Netherlands). 2024 Jan;187:107414. PubMed PMID: 38088015. Epub 2023/12/13. eng.
    Journal
    Lung Cancer
    URI
    http://hdl.handle.net/10541/626814
    DOI
    10.1016/j.lungcan.2023.107414
    PubMed ID
    38088015
    Additional Links
    https://dx.doi.org/10.1016/j.lungcan.2023.107414
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.lungcan.2023.107414
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
    • Authors: Naidoo J, Antonia S, Wu YL, Cho BC, Thiyagarajah P, Mann H, Newton M, Faivre-Finn C
    • Issue date: 2023 May
    • Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    • Authors: Gelatti ACZ, Drilon A, Santini FC
    • Issue date: 2019 Nov
    • A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
    • Authors: Choi J, Lee JE, Choi CM, Oh IJ, Lee KY, Jang TW, Lee SH, Kim EY, Park DW, Park SH, Lee SY
    • Issue date: 2022 Dec
    • Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
    • Authors: Frampton JE
    • Issue date: 2022 May
    • Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
    • Authors: Agulnik JS, Kasymjanova G, Pepe C, Hurry M, Walton RN, Sakr L, Cohen V, Small D
    • Issue date: 2021 Dec 7
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.